

Freedom of Information request 204-18

Request

1. Has your trust accepted or is it currently accepting manufacturer provision of free of charge drug stock between licensing and NICE funding? [Yes/No]

2. Has your trust accepted or is it currently accepting the following list of drugs in psoriasis:

Brodalumab [Kyntheum]	[Yes/No]
Guselkumab [Tremfya]	[Yes/No]
Ixekizumab [Taltz]	[Yes/No]
Secukinumab [Cosentyx]	[Yes/No]

3. Has your trust accepted or is it currently accepting the following list of drugs in Rheumatoid Arthritis:

Tofacitinib [Xeljanz]	[Yes/No]
Baricitinib [Olumiant]	[Yes/No]
Golimumab [Simponi]	[Yes/No]
Certolizumab [Cimzia]	[Yes/No]
Apremilast [Otezla]	[Yes/No]
Tocilizumab [Ro Actemra]	[Yes/No]

4. Has your trust accepted or is it currently accepting the following list of drugs in Ankylosing Spondylitis or Psoriatic Arthritis:

Secukinumab [Cosentyx]	[Yes/No]
------------------------	----------

5. Has your trust accepted or is it currently accepting the following list of drugs in Ulcerative Colitis:

Golimumab [Simponi]	[Yes/No]
---------------------	----------

6. If your trust has not accepted manufacturer provision of free of charge drug stock, what have been the reasons for this? [.....]

7. In future, will your trust be able to accept manufacturer provision of free of charge drug stock? [Yes/No]

8. What is the preferred distribution channel for the provision of free of charge drug stock?

Homecare	[Yes/No]
----------	----------

Delivered directly to hospital/Trust	[Yes/No]
--------------------------------------	----------

Other (please provide details)	[.....]
--------------------------------	---------

9. For how long is free of charge drug stock typically provided for each patient ?

first dose	[Yes/No]
------------	----------

first month	[Yes/No]
-------------	----------

first 3 months	[Yes/No]
----------------	----------

Other [.....]	
---------------	--

Clarification Received:

Questions 2-5 relate to free of charge drug stock for the specific disease and drug.

Response

1. No.

2-5. Not applicable.

6. The Board does not accept free stock unless through national agreed arrangements.

7. No, unless through nationally agreed arrangements.

8-9. Not applicable.

If you are not satisfied with the way your request has been handled or the decision given, you may ask NHS Borders to review its actions and the decision. If you would like to request a review please apply in writing to, Freedom of Information Review, NHS Borders, Room 2EC3, Education Centre, Borders General Hospital, Melrose, TD6 9BS or foi.enquiries@borders.scot.nhs.uk.

The request for a review should include your name and address for correspondence, the request for information to which the request relates and the issue which you wish to be reviewed. Please state the reference number **204-18** on this request. Your request should be made within 40 working days from receipt of this letter.

If following this review, you remain dissatisfied with the outcome, you may appeal to the Scottish Information Commissioner and request an investigation of your complaint. Your request to the Scottish Information Commissioner should be in writing (or other permanent form), stating your name and an address for correspondence. You should provide the details of the request and your reasons for dissatisfaction with both the original response by NHS Borders and your reasons for dissatisfaction with the outcome of the internal review. Your application for an investigation by the Scottish Information Commissioner must be made within six months of your receipt of the response with which you are dissatisfied. The address for the Office of the Scottish Information Commissioner is, Office of the Scottish Information Commissioner, Kinburn Castle, Doubledykes Road, St Andrews, Fife.